Dr. Reddy’s Laboratories reported consolidated revenues of ₹335.9 billion for the full financial year 2025-26, reflecting 3.2% annual growth. While the fourth quarter faced headwinds, with revenues at ₹75.2 billion, the company remains focused on its long-term strategy of portfolio optimization and growth in biosimilars. The Board has recommended a final dividend of ₹8 per equity share, subject to shareholder approval.
Annual and Quarterly Performance
For the financial year ended March 31, 2026, Dr. Reddy’s Laboratories achieved total consolidated revenues of ₹335.9 billion, a 3.2% increase over the previous year. The fourth quarter, however, saw revenues of ₹75.2 billion. The performance throughout the year was impacted by several one-offs, including lower Lenalidomide sales and adjustments, though these were partially mitigated by strong branded business performance and currency tailwinds.
Segment Insights
The Global Generics segment remained a cornerstone, posting full-year revenues of ₹299.0 billion, a 3% growth. The India market showed significant resilience, with revenue growing 16% to ₹62.2 billion, driven by successful new brand launches and increased volumes. Meanwhile, the Europe market achieved a notable 55% growth, reaching ₹55.5 billion for the year, bolstered by contributions from the Nicotine Replacement Therapy (NRT) portfolio.
Strategic Priorities and Dividend
Despite quarterly fluctuations, the company continues to invest in complex generics, biosimilars, and innovation. The Board of Directors has recommended a final dividend of ₹8 per equity share for the 2025-26 financial year, with a record date for eligible members set for July 10, 2026.
Leadership and Governance Updates
In addition to financial results, the company announced key governance updates, including the re-appointment of Dr. K.P. Krishnan and the appointment of Mr. Srikanth Velamakanni as Independent Directors. Furthermore, Mr. Sandeep Khandelwal has been elevated to the role of Senior Management Personnel, effective May 12, 2026, to further strengthen the company’s leadership in the Indian market.
Source: BSE
